"If that study successfully demonstrates a clinical benefit for PTX-100, the drug could advance directly into another study that could be suitable for registration.Compared to the usual large Phase 3 studies, a comparatively smaller trial might be all that’s needed to register the drug, Prescient says.Yatomi-Clarke says the company is pursuing the quickest route to market for PTX-100 by pursuing areas of unmet clinical need."
Has anybody else noticed this in the * article? Seems quite significant and that the market may have over-reacted about not reaching a phase 2+3 combined trial.
More than 1 way to skin a cat?
PTX Price at posting:
18.5¢ Sentiment: Hold Disclosure: Held
